Case study / Employer outcome

Founder-to-Exit Specialty Pharmacy

Mineral discs linked by a fine thread and a sequence of suspended droplets — *Coordinated flow*Therapy & transactions

Founder ownership across specialty-pharmacy growth, reimbursement, operating controls and strategic divestiture.

Return to verified work

Evidence register

What this case can support.

Evidence class: Employer outcome
Claim boundary: Aggregate results are reported in the September 12, 2026 executive resume. The resume is the source of these claims; no independent verification, buyer endorsement, or private transaction terms are asserted.
Source basis: September 12, 2026 executive resume
Founder operating record
Accreditation and diligence history

Case architecture

Ecosystem thesis

As co-founder and COO, I had to make commercial growth, reimbursement, inventory and fulfillment support the same financial model. Drug mix could increase revenue while consuming cash; automation could expand throughput while leaving access or purchasing constraints unresolved. Full P&L ownership made those interactions part of the daily operating decision.

System path

01Problem
02Build
03Scale
04Accredit
05Automate
06Exit

Executive decision brief

CEO question

Which growth can the pharmacy finance and deliver while preserving margin, quality and transaction readiness?

Operating answer

My founder discipline is to assess growth through contribution, working capital and operational reliability together. I would expand a therapy or payer relationship only after understanding its acquisition cost, reimbursement exposure, inventory funding and service obligations. That same evidence makes the business legible in diligence.

Proof to inspect

My reported operating record covers company formation, margin management, URAC accreditation, ScriptPro automation, dispensing reliability and strategic divestiture to Rite Aid. These are distinct elements of the record. The financial and operating measures retain their résumé-based scope; they do not establish the isolated contribution of any single intervention.

Ecosystem context

The conditions that shaped the work.

Specialty pharmacy sits at the intersection of clinical complexity, reimbursement control, patient adherence, drug-cost volatility, and provider workflow. A business can show top-line prescription growth and still fail if payer rules, accreditation, inventory, claims discipline, or dispensing accuracy break under scale.

The commercial challenge was therefore not simply to acquire volume. It was to build a financeable healthcare asset: one that could win provider trust, survive payer/PBM scrutiny, manage complex therapies, document compliance, protect margin, and remain clean enough for strategic-buyer diligence.

The same discipline applies when a healthtech company moves beyond early product demand. Reimbursement, implementation, compliance and evidence must support repeatable delivery before the organization commits to broader expansion.

Stakeholder tensions

The people and pressures shaping the work.

Patients

Needed access, adherence support, and reliable therapy fulfillment.

Complex therapies fail when access friction, prior authorization, or fulfillment delay interrupts the care path.

Prescribers

Needed a trusted fulfillment partner who could handle specialty workflows without creating office burden.

Provider confidence depends on speed, accuracy, communication, and low administrative drag.

Payers / PBMs

Controlled network access, reimbursement rules, utilization logic, and contract economics.

Revenue growth had to be filtered through margin discipline and contract durability.

Accreditation / Compliance

Set the operating standard for quality, documentation, and specialty pharmacy readiness.

Compliance could not be a retrofit; it had to be embedded before diligence.

Strategic Buyer

Needed a clean, scalable, diligence-ready asset.

An exit requires operational truth, not only growth narrative.

Outcome record

The proof signals attached to the case.

founderFounder build

Annualized revenue

Scaled from $0 to $8M+ annualized revenue with full P&L accountability and a 25-person team, as reported in the resume.

operationsMargin discipline

EBITDA

Sustained 18%+ EBITDA through payer/PBM economics and operating discipline.

operationsAutomation discipline

Accuracy

ScriptPro automation increased throughput 150% with 99.97% accuracy.

payerAccess expansion

Covered lives

Expanded complex-therapy access to 10,000 covered lives; secured URAC accreditation.

Interoperability map

How the layers connect.

Follow how the market signal informs the economics, how the workflow responds, and what evidence supports the next decision.

Demand

Where does provider and patient need concentrate?

Complex therapy demand was converted into trusted referral and fulfillment workflows rather than loose volume.

Reimbursement

Can the revenue survive payer and PBM economics?

Contracting, drug mix, and margin discipline were managed as operating controls, not back-office afterthoughts.

Operations

Can the platform fulfill accurately at scale?

ScriptPro automation, inventory governance, staffing, and workflow design protected throughput and accuracy.

Diligence

Can the asset withstand buyer review?

Accreditation, compliance documentation, and operational cleanup made the business legible to a strategic acquirer.

Operating record

The work, the sequence, and the strategic read.

Read the starting conditions, the work performed and the strategic interpretation separately. Together, they explain both the decision and the limits of the evidence.

Challenge

Build a specialty pharmacy platform in a regulated environment where payer/PBM contracting, 340B, compliance, patient access, inventory, and provider trust all had to work together.

Approach

Built the operating model from the ground up: licensing, workflows, reimbursement controls, accreditation readiness, dispensing automation, provider partnerships, and full P&L discipline.

Founder takeaway

Strategic read

A buyer, payer or enterprise customer needs to understand how growth is earned and sustained. Financial controls, compliance records and dependable fulfillment make that assessment possible; they belong in the business from the outset.

Proof interpretation

Operator moves

Owned full P&L and revenue-quality discipline instead of treating growth as top-line volume only.
Built payer/PBM contracting, drug mix, inventory, and staffing controls around contribution margin.
Secured URAC specialty pharmacy accreditation and created buyer-ready compliance documentation.
Implemented ScriptPro robotics to automate throughput while protecting dispensing accuracy.
Prepared diligence, integration planning, operational cleanup, and data rooms for strategic exit.

Expansion path

01
Start with one trusted clinical and provider workflow.
02
Add reimbursement and margin controls before growth obscures unit economics.
03
Operationalize accreditation, documentation, and quality before outside diligence.
04
Automate the repeatable workflow only after the workflow is understood.
05
Package the business as a system a strategic buyer can understand and integrate.

What I would do again

Build the diligence archive early.
Tie automation to margin and accuracy, not novelty.
Keep accreditation and payer documentation buyer-ready before a transaction process starts.

The decision principle

My responsibility was to build a business whose reimbursement, operations and financial controls could support continued service and withstand a strategic transaction. I read the outcome through that full operating responsibility, rather than revenue growth in isolation.

Evidence objects

Proof artifacts

Executive resume

Discuss a related mandate

Bring the decision into focus.

For healthcare leaders connecting market choices, payer economics, partnerships and delivery capacity to an accountable plan.

Contact Azis Download Resume